Supplementary Figures S1-S6 from Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition
Year: 2023
Type: supplementary-materials
Abstract: NSCLC harboring EGFR kinase domain mutation develops EGFR TKI resistance with mesenchymal phenotype (S1); Chronic exposure of HCC4006 cells to TGFβ1 promotes EMT and gefitinib resistance (S2); Chronic EGFR inhibition in EGFR mutant NSCLC cells promotes TGFβ1 secretion and SMAD pathway activation (S3); Concurrent EGFR and TGFβR inhibition prevents mesenchymal transition but does not avert emergence of EGFR TKI resistance (S4); AZD9291 treatment induces significant apoptosis in HCC4006GeSB-R cells with acquired T790M mutation (S5); Distribution of cells harboring T790M in PC9 and HCC4006 cells and STR analysis for HCC4006 cells and HCC4006 gefitinib resistant cells (S6).
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361848796